Table 1 The HLRCC-RCC patients with immunotherapy
Reference | Design | N | line | Histology (N) | Treatment | ORR (%) | PFS (m) | OS (m) |
|---|---|---|---|---|---|---|---|---|
Wang t al [14]. | Retrospective | 1 | 1 L | HLRCC-RCC | pembrolizumab | 100 | NR | NR |
Iribe et al. [13] | Retrospective | 1 | 1 L | HLRCC-RCC | Nivolumab + ipilimumab | 100 | NR | NR |
Yonese et al. [4] | Retrospective | 1 | > 1 L | HLRCC-RCC | Axitinib + Nivolumab | 100 | NR | NR |
Feng et al. [16] | Retrospective | 1 | 1 L | HLRCC-RCC | Sintilimab + Axitinib | 100 | NR | NR |
Gleeson et al. [17] | Retrospective | 3 | > 1 L | HLRCC-RCC | ICI = 2 ICI + TKI = 1 | ICI = 0 ICI + TKI = 100 | NA | NA |
Sun et al. [18] | Retrospective | 5 | 1 L | HLRCC-RCC | ICI + TKI | 16.7 | 13.3 | NR |
Lee et al. [12] | Phase 2 | 5 | 1 L | HLRCC-RCC | Cabozantinib + Nivolumab = 5 | 100 | NA | NA |
Carril et al. [11]. | Retrospective | 11 | 1 L/>1 L | HLRCC-RCC | ICI | 18 | 2.7 | NA |
Xu et al. [10]. | Retrospective | 48 | 1 L/>1 L | HLRCC-RCC | ICI + TKI | 33 | 18 | NR |